Drugmaker Eli Lilly walks back 2024 forecast after 3Q earnings miss

  • 📰 wjxt4
  • ⏱ Reading Time:
  • 37 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 18%
  • Publisher: 63%

Business News

Business Business Latest News,Business Business Headlines

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations.

LIVE: Secretary of State Brad Raffensperger gives update on early voting after Georgians break 3 million mark

Read full article: LIVE: Secretary of State Brad Raffensperger gives update on early voting after Georgians break 3 million markEstranged couple accused in murder-for-hire plot appears in court for pre-trial hearingKeep your drink cold longer with these tumblers. See more Insider Deals here.Looking to save on items for your home, road trip and wardrobe? We've got the latest Insider Deals to share!FILE - This April 26, 2017 file photo shows the Eli Lilly & Co.

Leerink Partners analyst David Risinger said separately that although Lilly’s results were disappointing, he is keeping his “outperform” rating on the stock. He noted that Lilly “is just getting started in commercializing obesity products globally.”

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 246. in BUSİNESS

Business Business Latest News, Business Business Headlines